Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evgeny Kulesskiy

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
The Journal of Cell Biology|August 16, 2006
N-syndecan deficiency impairs neural migration in brainAnni Hienola, Sarka Tumova, Evgeny Kulesskiy, et al.
Journal of Laboratory Automation|January 2, 2016
Precision Cancer Medicine in the Acoustic Dispensing Era: Ex Vivo Primary Cell Drug Sensitivity TestingEvgeny Kulesskiy, Jani Saarela, Laura Turunen, et al.
Methods in Molecular Biology (Clifton, N.J.)|January 19, 2018
Methods for High-throughput Drug Combination Screening and Synergy ScoringLiye He, Evgeny Kulesskiy, Jani Saarela, et al.
Antimicrobial Agents and Chemotherapy|November 27, 2013
Antifungal application of nonantifungal drugsMarios Stylianou, Evgeny Kulesskiy, José Pedro Lopes, et al.
Translational Oncology|September 17, 2022
Functional temozolomide sensitivity testing of patient-specific glioblastoma stem cell cultures is predictive of clinical outcomeErlend Skaga, Evgeny Kulesskiy, Swapnil Potdar, et al.
The Journal of Cell Biology|January 5, 2011
Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and arteminMaxim M Bespalov, Yulia A Sidorova, Sarka Tumova, et al.
Clinical and Translational Medicine|January 1, 2020
Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatmentErlend Skaga, Evgeny Kulesskiy, Marit Brynjulvsen, et al.
Scientific Reports|September 10, 2016
HMGB4 is expressed by neuronal cells and affects the expression of genes involved in neural differentiationAri Rouhiainen, Xiang Zhao, Päivi Vanttola, et al.
Scientific Reports|June 6, 2014
Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapiesBhagwan Yadav, Tea Pemovska, Agnieszka Szwajda, et al.
BMC Cancer|June 27, 2019
Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastomaErlend Skaga, Evgeny Kulesskiy, Artem Fayzullin, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
The Journal of Cell Biology|August 16, 2006
N-syndecan deficiency impairs neural migration in brainAnni Hienola, Sarka Tumova, Evgeny Kulesskiy, et al.
Journal of Laboratory Automation|January 2, 2016
Precision Cancer Medicine in the Acoustic Dispensing Era: Ex Vivo Primary Cell Drug Sensitivity TestingEvgeny Kulesskiy, Jani Saarela, Laura Turunen, et al.
Methods in Molecular Biology (Clifton, N.J.)|January 19, 2018
Methods for High-throughput Drug Combination Screening and Synergy ScoringLiye He, Evgeny Kulesskiy, Jani Saarela, et al.
Antimicrobial Agents and Chemotherapy|November 27, 2013
Antifungal application of nonantifungal drugsMarios Stylianou, Evgeny Kulesskiy, José Pedro Lopes, et al.
Translational Oncology|September 17, 2022
Functional temozolomide sensitivity testing of patient-specific glioblastoma stem cell cultures is predictive of clinical outcomeErlend Skaga, Evgeny Kulesskiy, Swapnil Potdar, et al.
The Journal of Cell Biology|January 5, 2011
Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and arteminMaxim M Bespalov, Yulia A Sidorova, Sarka Tumova, et al.
Clinical and Translational Medicine|January 1, 2020
Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatmentErlend Skaga, Evgeny Kulesskiy, Marit Brynjulvsen, et al.
Scientific Reports|September 10, 2016
HMGB4 is expressed by neuronal cells and affects the expression of genes involved in neural differentiationAri Rouhiainen, Xiang Zhao, Päivi Vanttola, et al.
Scientific Reports|June 6, 2014
Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapiesBhagwan Yadav, Tea Pemovska, Agnieszka Szwajda, et al.
BMC Cancer|June 27, 2019
Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastomaErlend Skaga, Evgeny Kulesskiy, Artem Fayzullin, et al.
Pageof 3